Loading...
Loading...
Peregrine Pharmaceuticals
PPHM shares fell 62.7% to 40 cents, after announcing it will discontinue the ongoing Phase III SUNRISE trial of bavituximab in patients with previously treated cell lung cancer. Share volume was 1.2 million, routing an all-day average of 211,000
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
